Meeder Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Meeder Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-390	Closed	-$181K	–	2083
2020 Q3	$181K	Hold	390	–	–	0.01%	635
2020 Q2	$228K	Buy	390 +170	+77%	+$58.1K	0.01%	568
2020 Q1	$32K	Buy	220 +164	+293%	+$28.7K	﹤0.01%	1068
2019 Q4	$8K	Sell	56 -24	-30%	-$1.75K	﹤0.01%	1633
2019 Q3	$3K	Buy	80 +67	+515%	+$4.87K	﹤0.01%	1884
2019 Q2	$1K	Buy	13 +1	+8%	+$118	﹤0.01%	1961
2019 Q1	$2K	Buy	+12	New	+$1.51K	﹤0.01%	1561
2018 Q1	–	Sell	-1	Closed	–	–	1672
2017 Q4	$0	Buy	+1	New	+$436	﹤0.01%	1742

Other funds holding MRSN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Meeder Asset Management's MRSN Position: Q4 2020 in Review

Meeder Asset Management sold out of Mersana Therapeutics (MRSN) in Q4 2020, closing a stake of 390 shares — an estimated $181K sold.

Meeder Asset Management first reported a position in MRSN in Q4 2017 and held it in 8 quarters. The position peaked at $228K in Q2 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

Meeder Asset Management reported no remaining Mersana Therapeutics position as of Q4 2020 after selling out during the quarter.
Meeder Asset Management sold 390 Mersana Therapeutics shares in Q4 2020, an estimated $181K.
Meeder Asset Management first reported a position in Mersana Therapeutics in Q4 2017 and held it in 8 quarters.
Meeder Asset Management's Mersana Therapeutics position peaked at $228K in Q2 2020.
151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.